Edison updated $PHO price target 70 NOK after Cevira partnershipOSL:PHO
Company press release about partnership deal URL:
twitter.com
Edison analyst update URL:
www.edisongroup.com
PCI Biotech $PCIB.OL testing breakout from yearlong downtrendPCI Biotech Holding OSL:PCIB stock has been consolidating in a trading range below last years 30 NOK shareprice rights issue of NOK 360 million.
Positive market reaction to the latest quarterly report from the company, along with good coverage in magasines:
www.tu.no (norwegian language)
nordiclifescience.org (page 91-94)
At the moment, the stock is testing a breakout from the old trading range, and longs will be keen to see further conference or scientific journal coverage of the ongoing clinical programs for the companys FimaCHEM and FimaVACC products, as well as partnering deals for its FimaNAC product.
Equinor CUP Reversal at 200MA into HANDLE, filling up gapI see a potential reversal of trend at the 200MA for equinor as it starts forming a cup and handle. Increased chances as it aims to fill up gap before resuming bullish trend.
All in nowMomentum is increasing and touching 0-line soon. RSI level is increasing and touching 50-line soon. Moving averages 50 & 100 also crossing each other upward soon.
AKER ASAWeekly 13 and 21 EMA about to meet on the MACD indicator. It is gaining momentum to the upside, whitch indicates a possible up-trend for the next months. The cycle has repeated itself two times before, and is likely to repeat now.
??
KjøpskandidatVelger å tro at denne er en kjøpskandidat på grunn av et underkjøpt marked. Veldig mye usikkerhet i markedet for tiden, men virker som at dette kommer til å endres snart. Når dette skjer vil jeg tro at DNO kommer til å være en av de som vil få et hopp. Kommer muligens i takt med en oppgang i oljeprisen. Virkelig verd å ha i porteføljen til denne prisen!
Photocure $PHO.OL stock pullback after Q2 is chance to buyPhotocure $PHO.OL OSL:PHO presented Q2 2019 numbers today, with most numbers landing very close to expectations.
Webcast: webtv.hegnar.no
Press release: newsweb.oslobors.no
Armchair Healthcare podcast interview with CEO Dan Schneider: twitter.com
NAS tradePerfekt for trading i noen dager, ligger i posisjon for en liten/middels oppgang. Middels rsi før slutten av en trend
GIG noen dagerLav RSI, ligger i ett underkjøpt marked. Muligens en oppgang iløpet av noen dager. Nylig gått gjennom en HS
Oppgang i TelenorLigger for tiden i et litt underkjøpt marked og har en relativt lav pris. RSI ligger på 54,05, så dersom man kjøper i dag eller etter neste nedgang(neste uke) vil man være med på en oppgang som varer ca 1-2mnd.
Photocure $PHO.OL renewed breakout watch ahead of Q2 reportInvestors are eagerly awaiting Photocures OSL:PHO Q2 2019 report to get a more indepth description of the recently announced Cevira partnership deal.
Also key is the information about the current growth rate on Cysview sales in US.
NOK 60-64 is a key level of expected resistance, as it is where the share price peaked in 2018, while a negative reaction could easily mean a pullback well below the NOK 50 level, which mean that an entry ahead of the upcoming Q2 presentation should be made with a keen eye on risk management.
Recent Edison Analysis after Cevira Deal announcement, BUY target price 70 NOK:
www.edisongroup.com
I think a pull back is comingI think we after seeing a 10% increase in one day, we will see a pullback to a lower level tomorrow.
We are closing a Fib resistant level.
Photocure $PHO.OL boost on chinese partnership dealPhotocure OSL:PHO today released news of a outlicensing of the Cevira franchise for commercialization, giving the stock a boost, possibly regaining foothold above the SMA50 and SMA200.
Press release
photocure.com
Targeting some further down sideI am targeting some further down side for NEL..
hopefully 3.72 will hold otherwise next support might be at 2.885
